MacuLogix
- Industry
- Medical Devices
- Founded Year
- 2004
- Headquarters
- Harrisburg, Pennsylvania, United States
- Employee Count
- 21
Key People
- Gregory R. Jackson - Chief Technology Officer
- Bill McPhee - President & CEO
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: The leadership team includes experienced professionals with significant industry experience.
The leadership team, including individuals like Gregory R. Jackson and Bill McPhee, brings substantial experience in the medical device industry, which is crucial for navigating the complexities of product development and market entry.
- Clinical Need
-
Aspect: Very Strong
Summary: Age-related macular degeneration (AMD) is a leading cause of blindness, indicating a significant clinical need.
AMD affects a large and growing population, and early detection is vital for preventing vision loss. MacuLogix's focus on early detection through dark adaptation measurement directly addresses this need.
- Competition
-
Aspect: Somewhat crowded
Summary: The market for AMD detection devices has multiple players, though MacuLogix offers unique technology.
While MacuLogix's AdaptDx Pro offers innovative features, the AMD detection market includes several established companies, necessitating strong differentiation and marketing strategies.
- Technical Challenge
-
Aspect: Predictable
Summary: The technology involves established principles of dark adaptation measurement.
Dark adaptation measurement is a known method in ophthalmology, and MacuLogix's implementation leverages existing scientific understanding, making technical challenges manageable.
- Patent
-
Aspect: Strong
Summary: The company holds multiple patents related to its technology.
MacuLogix has developed 16 U.S. patents and 46 international patents, offering substantial intellectual property protection for its products.
- Financing
-
Aspect: Medium
Summary: The company has raised significant funding but faced financial challenges leading to acquisition.
Despite raising approximately $64.3 million in funding, MacuLogix encountered liquidity issues exacerbated by the COVID-19 pandemic, leading to the winding down of operations and eventual acquisition by LumiThera.
- Regulatory
-
Aspect: 510k/PMA
Summary: The company's products have received necessary regulatory approvals.
MacuLogix's AdaptDx Pro has obtained regulatory clearances, enabling its use in clinical settings for AMD detection.
Opportunity Rollup
- Odds of Success
- 3.95
- Peak Market Share
- 5.3
- Segment CAGR
- 3.2%
- Market Segment
- Ophthalmic Devices
- Market Sub Segment
- AMD Detection Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.27 |
| 2 | 0.80 |
| 3 | 1.86 |
| 4 | 3.71 |
| 5 | 5.30 |
Key Takeaway
MacuLogix's innovative approach to early AMD detection addresses a significant clinical need, but financial challenges and market competition pose risks to its success.